95.23 - 97.14
55.47 - 103.81
1.63M / 1.80M (Avg.)
55.57 | 1.74
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.14%
Negative revenue growth while NEM stands at 15.71%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.47%
Negative gross profit growth while NEM is at 27.70%. Joel Greenblatt would examine cost competitiveness or demand decline.
-7.96%
Negative EBIT growth while NEM is at 52.45%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-7.96%
Negative operating income growth while NEM is at 52.45%. Joel Greenblatt would press for urgent turnaround measures.
-5.12%
Negative net income growth while NEM stands at 152.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Share change of 0.05% while NEM is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
1.31%
Diluted share change of 1.31% while NEM is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-14.11%
Negative OCF growth while NEM is at 221.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-14.11%
Negative FCF growth while NEM is at 146.07%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
46.59%
10Y revenue/share CAGR above 1.5x NEM's 29.05%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
24.76%
5Y revenue/share CAGR at 50-75% of NEM's 38.55%. Martin Whitman would worry about a lagging mid-term growth trajectory.
36.40%
3Y revenue/share CAGR at 75-90% of NEM's 43.84%. Bill Ackman would expect new product strategies to close the gap.
No Data
No Data available this quarter, please select a different quarter.
216.23%
5Y OCF/share CAGR above 1.5x NEM's 96.19%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-45.21%
Negative 3Y OCF/share CAGR while NEM stands at 59.20%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
219.86%
3Y net income/share CAGR 50-75% of NEM's 371.86%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
196.05%
10Y equity/share CAGR above 1.5x NEM's 114.27%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
188.63%
5Y equity/share CAGR 1.25-1.5x NEM's 146.53%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
291.55%
3Y equity/share CAGR above 1.5x NEM's 39.75%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.63%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
No Data
No Data available this quarter, please select a different quarter.
4.08%
Similar asset growth to NEM's 3.88%. Walter Schloss finds parallel expansions or investment rates.
4.14%
Similar to NEM's 4.21%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.33%
We cut SG&A while NEM invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.